Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
R&D Systems™ Human CXCL2/GRO beta/MIP-2/CINC-3 aa 35-107 Recombinant Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Supplier: R&D Systems™ 276GB010/CF
This item is not returnable.
View return policy
Description
The Recombinant Human CXCL2/GRO beta Protein is derived from E. coli. The Recombinant Human CXCL2/GRO beta Protein has been validated for the following applications: Bioactivity.Specifications
| Lyophilized from a 0.2μm filtered solution in Acetonitrile and TFA. | |
| 8 kDa | |
| 10μg | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution. | |
| Recombinant |
| 2920 | |
| CXCL2/GRO beta/MIP-2/CINC-3 aa 35-107 | |
| E. coli-derived human CXCL2/GRO beta/MIP-2/CINC-3 protein Ala35-Asn107 | |
| Unconjugated | |
| 97%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Product Title